Carcinoid syndrome medical therapy

Carcinoid syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Carcinoid Syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Staging
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Carcinoid syndrome medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Carcinoid syndrome medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Carcinoid syndrome medical therapy
CDC on Carcinoid syndrome medical therapy
Carcinoid syndrome medical therapy in the news
Blogs on Carcinoid syndrome medical therapy
Directions to Hospitals Treating Carcinoid syndrome
Risk calculators and risk factors for Carcinoid syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Parminder Dhingra, M.D. [2]

Overview

For symptomatic relief of carcinoid sydromes medical therapy many include: octreotide, methysergide maleate, and cyproheptadine.

Medical Therapy

Standard treatments for patients with gastrointestinal (GI) carcinoid tumors include the following:

Surgery. Somatostatin analogs. Interferons. Treatment of hepatic metastases. Radionuclides. Management of carcinoid-related fibrosis. Symptomatic therapy. Symptomatic relief may be provided by any of the following medical therapies:

• Octreotide (somatostatin analogue- neutralizes serotonin and decreases urinary 5-HIAA)
• Methysergide maleate (antiserotonin agent but not used because of serious side effect of retroperitoneal fibrosis)
• Cyproheptadine (antihistamine)

Chemotherapy

Chemotherapy is of little benefit and is generally not indicated. Octreotide (a somatostatin analogue) may decrease the secretory activity of the carcinoid.

References

Template:WikiDoc Sources